Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 375 followers
Latest posts
Last updated 8 days ago
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
8 days ago
Filing acceptance based on phase III data showing giredestrant plus everolimus reduced...
Invitation to Roche’s Virtual Immunology/SLEuro Investor Event
11 days ago
We are pleased to invite investors and analysts to participate in our...
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
12 days ago
MAJESTY, the first global phase III study in primary membranous nephropathy, met...
Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
20 days ago
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met...
Reminder: Invitation to Roche’s Virtual Neurology/ACTRIMS Investor Event
26 days ago
We are pleased to invite investors and analysts to participate in our...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
30 days ago
Group sales grew by 7%1 at constant exchange rates (CER; 2% in...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
30 days ago
Group sales grew by 7%1 at constant exchange rates (CER; 2% in...
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
about 1 month ago
A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight...
Reminder: Invitation to Roche’s Full Year Results 2025 Presentation
about 1 month ago
Roche will publish its Full Year Results of 2025 prior to the...
Invitation to Roche’s Virtual Neurology/ACTRIMS Investor Event
about 2 months ago
We are pleased to invite investors and analysts to participate in our...
Invitation to Roche’s Full Year Results 2025 Presentation
about 2 months ago
Roche will publish its Full Year Results of 2025 prior to the...
FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
2 months ago
Lunsumio VELO reduces administration time from 2-4 hours to approximately one minuteAvailability...